Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma

BACKGROUND: The survival and therapeutic outcome vary greatly among glioblastoma (GBM) patients. Treatment resistance, including resistance to temozolomide (TMZ) and radiotherapy, is a great obstacle for these therapies. In this study, we aimed to evaluate the predictive value of SEC61G on survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Bo, Liu, Jingping, Liao, Yuxiang, Jin, Chen, Zhang, Zhiping, Zhao, Jie, Liu, Kun, Huang, Hao, Cao, Hui, Cheng, Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2019
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536036/
https://www.ncbi.nlm.nih.gov/pubmed/31094363
http://dx.doi.org/10.12659/MSM.916648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536036/
https://www.ncbi.nlm.nih.gov/pubmed/31094363
http://dx.doi.org/10.12659/MSM.916648

Ejemplares similares